Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Aug 2, 2021- FreeStyle Libre 2 iOS app is the only sensor-based glucose monitoring app that allows users to check their glucose with a compatible iPhone[1] every minute with optional real-time glucose alarms[2]- The FreeStyle Libre 2 app enables kids (ages 4 and older) and adults to easily share their glucose data with parents and other caregivers via the LibreLinkUp[3] app- Free to download on the App Store, the FreeStyle Libre 2 iOS app will be available soon-
Jul 29, 2021- Jot Dx™ Insertable Cardiac Monitor (ICM) expands Abbott's connected care portfolio and is the first and only device on the market with the option to control the amount of electronic data received for irregular heart rhythms, depending on the unique needs of the patient or clinic- Jot Dx™ ICM connects via Bluetooth with Abbott’s myMerlin™ mobile app for continuous remote monitoring, leading to a faster time to diagnosis compared to ICMs that may use traditional bedside monitors1- Abbott’s personalized concierge service, SyncUp™, provides one-on-one device setup support, helping patients connect Jot Dx™ ICM with the mobile app at home, taking the burden off physicians and clinic staff
Jul 29, 2021- Patients with diabetes who did not meet the recommended daily intake of protein had greater physical limitations, which together may suggest an increased risk of muscle loss- Abbott's line of nutrition products scientifically designed for people with diabetes now includes Glucerna® 30g protein shakes to help people with diabetes meet important daily protein consumption goals- Jul 22, 2021- Sales growth of 39.5 percent; organic sales growth of 35.0 percent- GAAP diluted EPS from continuing operations growth of 120.0 percent; adjusted diluted EPS growth of 105.3 percent- Second-quarter sales, excluding COVID-19 testing-related sales, grew 12.3 percent on a reported basis and 11.3 percent on an organic basis compared to sales in 2019- Achieved strong sales growth across all four major business areas- Full-year forecast continues to reflect strong, double-digit EPS growth on both a GAAP and adjusted basis
- Jun 30, 2021- New labeling approval for Abbott's XIENCE™ stent builds on a legacy of safety and allows for one-month (as short as 28 days) dual anti-platelet therapy (DAPT) for patients at high bleeding risk (HBR)- The new XIENCE Skypoint™ stent received FDA approval in the U.S. and CE Mark approval in Europe- XIENCE stents have 10+ years of clinical data across 120 clinical trials, more than 125,000 patients and 15 million stent¹ implants
-
Jun 28, 2021- Panbio™ COVID-19 Antigen Self-Test is approved for sale directly to consumers and for use in adults and children with or without symptoms, enabling fast, convenient coronavirus testing- The self-test features a minimally invasive nasal swab and delivers results in as early as 15 minutes with no instrumentation, using proven Abbott lateral flow technology- In clinical evaluations with self-test users, the Panbio Self-Test correctly identified 95.2% of positive samples and 100% of negative samples- Abbott is the only diagnostics manufacturer to provide performance data on a rapid antigen test specific for use on children who are 15 years and younger, including infants- Together with vaccines and health protocols, frequent, regular screening of asymptomatic and symptomatic people can restore a sense of safety and stability as more people return to work, school, family gatherings and recreational activities
- Jun 25, 2021- Comparative data presented at the American Diabetes Association 81st Scientific Sessions show Abbott's diabetes technology delivers the same reductions of HbA1c and acute complications(1,2) as the competitor systems while reaching a much wider, more diverse population- Priced at a third of the cost of other available continuous glucose monitoring systems(3), data suggests increasing use of FreeStyle Libre system could save Medicaid millions annually(4) by reducing costly complications- The groundbreaking FreeStyle Libre portfolio has been extensively studied with real-world data from more than 1 million users(5) and clinical evidence, showing it helps people with diabetes significantly improve their health and quality of life(6)
- Jun 24, 2021- Survey reveals nearly half of people who report regular, intense exercise believe that energy drinks and soda can aid in rehydration after exercising; however, these beverages do not meet scientific experts' recommendations for rehydration¹,²,³- Abbott, maker of Pedialyte®, teams up with fitness coach Jeanette Jenkins to encourage smart hydration
Jun 22, 2021Abbott Earns First-of-its-Kind Recommendation for High School STEM Interns to Receive College Credit- Abbott's summer program is the American Council on Education's first high school STEM internship eligible for post-secondary education credit recommendation- First-of-its-kind college credit opportunity provides model other companies can follow to give students a head start on earning STEM degrees- Students who successfully complete Abbott's internship after their senior year of high school are eligible to apply for credit from their educational institutions